Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

Journal article

PURPOSE: Vandetanib [vascular endothelial growth factor (VEGF) receptor/epidermal growth factor receptor/RET inhibitor] has shown improvements in progression-free survival (PFS) in advanced non-small cell lung cancer in three randomized phase II studies: vandetanib versus gefitinib (study 3), docetaxel +/- vandetanib (study 6), and carboplatin-paclitaxel and/or vandetanib (study 7). In study 7, vandetanib monotherapy was inferior to carboplatin-paclitaxel. We performed an exploratory retrosp...

Expand abstract

Authors: Hanrahan, E; Ryan, A; Mann, H; Kennedy, S; Langmuir, P

• Publication status: Published
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
• Volume: 15
• Issue: 10
• Pages: 3600-3609
• Publication date: 2009-05-01
• DOI: 10.1158/1078-0432.ccr-08-2568
• EISSN: 1557-3265
• ISSN: 1078-0432
• Language: English
• Keywords: Piperidines; Receptors, Vascular Endothelial Growth Factor; Clinical Trials, Phase II as Topic; Lung Neoplasms; Quinazolines; Vascular Endothelial Growth Factor A; Kaplan-Meier Estimate; Carcinoma, Non-Small-Cell Lung; Treatment Outcome; Predictive Value of Tests; Enzyme-Linked Immunosorbent Assay; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Humans; Antineoplastic Combined Chemotherapy Protocols; Tumor Markers, Biological